Athira Pharma, Inc. announced that the plans to further extend the current OLEX for the Phase 2/3 LIFT-AD and Phase 2 ACT-AD trials of fosgonimeton for the treatment of mild-to-moderate AD by an additional 12 months. Following this extension, eligible participants who have completed the LIFT-AD or ACT-AD trials and elect to participate in the ongoing OLEX will be able to receive up to 30 months of open-label treatment. This extension is intended to address investigator and patient interest in continuing treatment with fosgonimeton beyond 18 months.

The company believe it will also further enhance long-term safety database and provide insights into fosgonimeton's long-term effects for up to 3 years. The OLEX continues to enroll with greater than 85% of participants who have completed either study having elected to enroll in the OLEX trial. The ACT-AD trial and the related open-label extension for ACT-AD participants was supported by a grant from the National Institute on Aging of the National Institutes of Health under Award Number R01AG06268.

The information presented in this release is solely the responsibility of Athira and does not necessarily represent the official views of the National Institutes of Health.